• DM type I and II:
  • Dose is individualized
  • Insulin-naïve patients:
    • Type 1: SC 0.2-0.4 units/kg/day
    • Type 2: SC 10 units OD
      • Initial dose: 1/3 to 1/2 of the total daily insulin requirement SC OD/BD with a main meal
      • The remaining total daily insulin requirement should be provided as a short or rapid-acting insulin divided and administered SC at meals in which this combination insulin is NOT administered
      • The initial total daily insulin requirement in insulin naive patients is generally 0.2 to 0.4 units of insulin per kilogram of body weight.
  • Switching from OD/BD premix insulin:
    • Initiate at the same dose units and injection schedule as the current premix
    • Short or rapid-acting insulin should be used for meals NOT covered by insulin degludec/insulin aspart
  • Switching from OD/BD basal insulin:
    • Initiate at the same dose units as the basal insulin OD/BD with a main meal of the day
    • Short or rapid-acting insulin should be used for meals NOT covered by insulin degludec/insulin aspart

Not recommended for treatment of diabetic ketoacidosis

Pre-filled syringe:

Insulin degludec 70 units/Insulin aspart 30 units per mL (100 units/mL)

  • Not to be diluted or mixed with any other insulin products or solutions
  • Patients with type I DM, will require a rapid or short-acting insulin at meals when insulin degludec/insulin aspart is not administered for optimal glucose control
  • Inject SC into the thigh, upper arm or abdomen
  • Injection sites should be rotated within the same region from 1 injection to the next to reduce the risk of lipodystrophy
  • The recommended days between dose increases is 3-4 days
  • An opened pen may be used for up to 28 days (4 weeks) after being opened, if it is kept at room temperature
  • When refrigerated, kept at 20-40C

Insulin degludec: Long-acting basal insulin

Insulin aspart: Rapid-acting insulin

It stimulates peripheral glucose uptake, inhibits hepatic glucose production, inhibits lipolysis and proteolysis regulating glucose metabolism

  • Nasopharyngitis
  • Severe hypoglycemia
  • Headache
  • URT infection
  • Influenza
  • Peripheral edema
  • Injection site reaction
  • Hypersensitivity to components
  • Hypoglycemia

None restricted

                          Drug Status

Availability Prescription only
Pregnancy Unknown; Use with caution
Breastfeeding Use with caution
Schedule Not controlled
BRAND NAME STRENGTH FORMULATION PACK SIZE MANUFACTURER DISTRIBUTOR
Ryzodeg Flextouch 70/30 IU/mL Injection 5*3mL Novo Nordisk Phillips Therapeutics